Tenderwize
Retour à la recherche

Open-house rebate agreement for Meropenem

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 05, 2027 · 188 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Meropenem, ATC J01DH02

52/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

52 / 100

Complexité

48 / 100

Facteurs de risque

Paper submissions are only treated as timely if the complete and correct originals arrive by the 10th of the month afte...

The buyer states that only pharmaceutical companies are eligible as potential contract partners.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Non-exclusive rebate agreements for the medicinal product Meropenem, ATC J01DH02.
  • Open-house model with identical, pre-set contract terms for all eligible pharmaceutical companies.
Afficher le résumé complet

This is an open-house pharmaceutical rebate agreement for Meropenem (ATC J01DH02) offered by AOK Bayern. It is not a competitive award procedure: the buyer states that all interested pharmaceutical companies meeting the stated suitability requirement can join on identical, non-negotiable terms. No contract value is stated. Submission is possible electronically via DTVP with a qualified electronic signature or in paper form in duplicate originals. The deadline for receipt of complete and correct documents is 2027-03-05 11:00, with monthly contract start mechanics described in the notice.

Risques

Paper submissions are only treated as timely if the complete and correct originals arrive by the 10th of the month afte...

The buyer states that only pharmaceutical companies are eligible as potential contract partners.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability/suitability must be submitted.
  • The signed contract and the completed annex 'Determination of the medicinal products covered by the contract' must be submitted.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for Meropenem

Single lot for non-exclusive open-house rebate agreements for the pharmaceutical product Meropenem, ATC J01DH02. The notice says the contract terms are identical and not individually negotiable. Performance is in Germany, specifically Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Apr 2025 - Apr 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Mar 05, 2027

Détails de la procédure

Date de publication
18 Mar 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
176004-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30